Defence Research and Development Organisation (DRDO) launched anti-Covid-19 drug 2-Deoxy-D-Glucose oral powder or 2-DG with Dr. Reddy’s laboratories. In this article, we will discuss about the DRDO’s anti-Covid drug 2-DG Approved, Efficacy, Price, Name. Drugs Controller General of India (DCGI) was testing DRDO anti-Covid-19 drug 2-DG over the Corona Virus and finally, they approved this drug for emergency use. In the initial weeks, the drug will be available in hospitals across metros and tier-1 cities
DRDO’s anti-Covid drug 2-DG
Table of Contents
The anti-Covid drug 2-deoxy-D-Glucose (2-DG) was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the DRDO, in collaboration with Dr. Reddy’s. It is an oral drug. Emergency use approval for the anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.
In June, Dr. Reddy’s Laboratories announced the commercial launch of the 2-DG drug. Dr. Reddy’s had said that it will supply the anti-Covid drug to major government hospitals as well as private hospitals across the country. “Anti-Covid drug 2-DG manufactured by Dr. Reddy has a purity of 99.5% and is being sold commercially under the brand name 2DGTM.
DRDO’s anti-Covid drug 2-DG Efficacy
A new study has claimed that 2-DG, the drug against coronavirus disease (Covid-19) developed by the Defence Research and Development Organisation (DRDO), is effective against all variants of Covid-19 and even reduces the multiplicity of the SARS-CoV-2 virus. The preliminary study also showed that DRDO’s anti-Covid drug alleviates cells from infection-induced cytopathic effect (CPE) and cell death, according to its abstract reviewed by news agency ANI.
DRDO’s Covid-19 drug, 2-deoxy-D-glucose (2-DG), was released amid much tucket by Union ministers Rajnath Singh and Dr. Harsh Vardhan on May 17. While releasing the first batch of DRDO’s anti-Covid drug, the central government claimed that the drug has the potential to reduce a patient’s average recovery time by two and a half days and oxygen demand by up to 40%. It was provided authorization for emergency use by the Drugs Controller General of India (DCGI) on June 1 as an adjunct therapy for moderate to severe coronavirus patients.
The new study assessing the viability of DRDO’s anti-Covid drug was conducted by Abhishek Kumar, Dhiviya Vedagiri, Annat Narayan Bhatt, Yogesh Rai, and others. It has not been peer-reviewed yet, ANI noted.
DRDO’s anti-Covid drug 2-DG – Price
Indian Government officials have said that DRDO’s anti-Covid drug 2-DG will be priced at ₹900 per sachet in the market, sold by the Hyderabad-based Dr. Reddy’s Laboratories (DRL), although it will provide the drug at discounted prices to the central and state governments.
- How the new variant of Corona becomes Omicron dangerous, WHO …
- UK to offer booster vaccine to all adults by the end of Janu…
- New variant of Corona arrived in Saudi Arabia after Brazil, …
- The discovery of the Omicron variant in southern Africa Raqu…
1) How did you develop the 2-DG drug?
Dr. Sudhir Chandana: We started working on 2-DG when the first wave of Covid-19 hit India in April 2020. We found that the drug stops the spread of coronavirus inside the body cells. After the findings, we asked the DCGI for permission to conduct clinical trials. In May 2020, we got permission for the clinical trials. By the end of October 2020, we had completed the second phase of trials, and the results were very good. Using standard care, the 2 DG will be more beneficial for the Covid-19 patients.
2) What do you mean by standard Care?
Dr. Sudhir Chandana: Standard care is the primary medicine used in hospitals for treating Covid patients.
3) Will the 2-DG drug be effective for patients with mild symptoms or moderate and serious symptoms?
Dr. Sudhir Chandana: Our trials were conducted on moderate and serious covid patients who were admitted to hospitals. All the patients benefitted, and no side effects were found. So it’s safe medicine. In the phase two trials, we found that the recovery rate of the patients was higher, and in the third phase, we observed reduced dependence on supplemental oxygen.
4)When will this drug be available to patients?
Dr. Sudhir Chandana: Our Industry Partner is Dr. Reddy’s Laboratories. We are working and trying together to expedite manufacturing. In a few weeks or within a month time, the medicine will be available for the patients.
5) How do 2-DG drugs control the coronavirus and reduce the dependence on oxygen?
Dr. Sudhir Chandana: The 2-DG drug-like glucose, spreads through the body, reaches the virus-infected cells, and prevents virus growth by stopping viral synthesis and destroying the protein’s energy production. The drug also works on virus infection spread into lungs which helps us to decrease patients’ dependability on oxygen.
6) Will the 2-DG drug affect the surge in covid cases and prevent deaths?
Dr. Sudhir Chandana: All the patients who participated in the trials have recovered from covid-19. Therefore, we hope that Covid patients will be benefitted from this drug.